Improving oncology practice and outcomes using Philips Clinical Pathways at RWJBarnabas Health (RWJBH) system.

607 Background: We report preliminary results from a pilot study prospectively evaluating the RWJBH experience with Philips Clinical Pathways (Philips) integration as an oncology decision support system within EPIC EHR. We note three main areas of improvement affecting patient care: physician adoption, “On-Pathway” adherent navigations, and decreased time to authorization. Methods: We infused large language models (LLM) and EPIC queries into our path analysis of clinical workflows, decision-making, and clinical trial matching. Results: Over the last 12 months, physician utilization has increased by 77%, with a total of 1026 navigations. The most navigated pathway was for genitourinary cancers, representing 23% of all navigations, followed by breast cancer (20%), gastrointestinal cancer (17%), and lung cancer (16%). Over 863 “On-Pathway” patient-specific navigations have been completed (84% of total) across all cancer types; 163 (16%) were designated as either “Clinical Trial” in 5% (n=50), “Off-Pathway” in 7% (n=74), or “Non-Pathway Diagnosis” in 4% (n=39). The 5 most frequent “On-Pathway” regimen selections are identified in the Table. We noted decreased time to authorization of treatment regimens for “On-Pathway” navigated patients. Conclusions: Real-world experience with voluntary use of an oncology decision support system demonstrates improvement in care coordination and management. We continue evaluations of patient care trajectories across treatment and survivorship, and for screening and enrollment to integrated cancer clinical trials. Additional data to be presented. Philips navigation: Top 5 regimen selections. Regimen Cancer Type Navigations Carboplatin/Paclitaxel Lung, Ovarian, Uterine/Endometrial, Head & Neck, Anal, Cervical 41 Pembrolizumab Breast, Melanoma, Anal, Colorectal, Esophageal, Bladder, Renal Cell, Uterine, Head & Neck, Lung 39 Cisplatin Head & Neck, Nasopharyngeal, Cervical, Urothelial 32 FOLFOX Colorectal, Biliary Tract, Esophageal 31 Abiraterone/Leuprolide Acetate/Prednisone Prostate 30

Authors

Institutions

Publication Details

Journal
JCO Oncology Practice
Published
2025-10-01
DOI
https://doi.org/10.1200/op.2025.21.10_suppl.607
Primary Topic
Economic and Financial Impacts of Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improving oncology practice and outcomes using Philips Clinical Pathways at RWJBarnabas Health (RWJBH) system.

Howard S. Höchster, Pérez Fuentes, Jacqueline Norrell, Andrew M. Evens et al.
JCO Oncology Practice
Economic and Financial Impacts of Cancer
article

Improving oncology practice and outcomes using Philips Clinical Pathways at RWJBarnabas Health (RWJBH) system.

Howard S. Höchster, Pérez Fuentes, Jacqueline Norrell, Andrew M. Evens, Missak Haigentz, Denine Izzi, Susan Solometo
article en

Abstract

607 Background: We report preliminary results from a pilot study prospectively evaluating the RWJBH experience with Philips Clinical Pathways (Philips) integration as an oncology decision support system within EPIC EHR. We note three main areas of improvement affecting patient care: physician adoption, “On-Pathway” adherent navigations, and decreased time to authorization. Methods: We infused large language models (LLM) and EPIC queries into our path analysis of clinical workflows, decision-making, and clinical trial matching. Results: Over the last 12 months, physician utilization has increased by 77%, with a total of 1026 navigations. The most navigated pathway was for genitourinary cancers, representing 23% of all navigations, followed by breast cancer (20%), gastrointestinal cancer (17%), and lung cancer (16%). Over 863 “On-Pathway” patient-specific navigations have been completed (84% of total) across all cancer types; 163 (16%) were designated as either “Clinical Trial” in 5% (n=50), “Off-Pathway” in 7% (n=74), or “Non-Pathway Diagnosis” in 4% (n=39). The 5 most frequent “On-Pathway” regimen selections are identified in the Table. We noted decreased time to authorization of treatment regimens for “On-Pathway” navigated patients. Conclusions: Real-world experience with voluntary use of an oncology decision support system demonstrates improvement in care coordination and management. We continue evaluations of patient care trajectories across treatment and survivorship, and for screening and enrollment to integrated cancer clinical trials. Additional data to be presented. Philips navigation: Top 5 regimen selections. Regimen Cancer Type Navigations Carboplatin/Paclitaxel Lung, Ovarian, Uterine/Endometrial, Head & Neck, Anal, Cervical 41 Pembrolizumab Breast, Melanoma, Anal, Colorectal, Esophageal, Bladder, Renal Cell, Uterine, Head & Neck, Lung 39 Cisplatin Head & Neck, Nasopharyngeal, Cervical, Urothelial 32 FOLFOX Colorectal, Biliary Tract, Esophageal 31 Abiraterone/Leuprolide Acetate/Prednisone Prostate 30

JCO Oncology PracticeVol. 21(10_suppl)
Rutgers, The State University of New Jersey (US), Rutgers Cancer Institute (US), Orion Corporation (United Kingdom) (GB)
Openalex Percentile: Top 63%
Economic and Financial Impacts of Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.